Medication Update:FDA approves first noninjection treatment for severe hypoglycemia

摘要

Baqsimi nasal powder has been approved as the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection. Baqsimi increases blood sugar levels by simulating the liver to release stored glucose into the bloodstream and is indicated for use in patients with diabetes age 4 years and older. Until now, people suffering from a severe hypoglycemic episode had to be treated with a glucagon injection that first had to be mixed in a multiple-stage process. Baqsimi simplifies that process, which is critical during a severe hypoglycemic episode, especially since the patient may have lost consciousness or may be having a seizure. In clinical trials comparing Baqsimi with a single dose of glucagon, Baqsimi was shown to effectively and safely increase blood sugar levels in both adults and children over age 4 years. Baqsimi, a product of Eli Lilly and Company, comes in a single-use dispenser.